Lymphoma

    Actionable Target Abnormality Clinical Experience with Targeted Agent
    PI3K Key signaling pathway Idelalisib (p110δ PI3K inhibitor):
    CLL:
    • Phase 3 rituximab–idelalisib vs. rituximab–placebo: ORR 81% vs. 13%, 12-mo OS 92% vs. 80% in relapsed-CLL (1)
    • Phase 3 idelalisib vs. placebo in combination with bendamustine and rituximab: mPFS 20.8 vs. 11.1 mo in rr-CLL (2)
    iNHL:
    • Phase 2: ORR 54% in FL, SLL 61%, MZL 47%; mPFS 11.0 mo; mOS 20.4 mo in refractory-iNHL (3)MCL:
    • Phase 1: ORR 40%, mPFS 3.7 mo in rr-MCL (4)
    Duvelisib (IPI-145; p110
    Other topics in Targets by Organ Site